Faculty, Staff and Student Publications

Publication Date

7-1-2024

Journal

Nature Cancer

DOI

10.1038/s43018-024-00768-3

PMID

38750245

PMCID

PMC12345446

PubMedCentral® Posted Date

8-13-2025

PubMedCentral® Full Text Version

Author MSS

Abstract

Chimeric antigen receptor (CAR) T cells used for the treatment of B cell malignancies can identify T cell subsets with superior clinical activity. Here, using infusion products of individuals with large B cell lymphoma, we integrated functional profiling using timelapse imaging microscopy in nanowell grids with subcellular profiling and single-cell RNA sequencing to identify a signature of multifunctional CD8+ T cells (CD8-fit T cells). CD8-fit T cells are capable of migration and serial killing and harbor balanced mitochondrial and lysosomal volumes. Using independent datasets, we validate that CD8-fit T cells (1) are present premanufacture and are associated with clinical responses in individuals treated with axicabtagene ciloleucel, (2) longitudinally persist in individuals after treatment with CAR T cells and (3) are tumor migrating cytolytic cells capable of intratumoral expansion in solid tumors. Our results demonstrate the power of multimodal integration of single-cell functional assessments for the discovery and application of CD8-fit T cells as a T cell subset with optimal fitness in cell therapy.

Keywords

Humans, Lymphoma, Large B-Cell, Diffuse, Single-Cell Analysis, Immunotherapy, Adoptive, CD8-Positive T-Lymphocytes, Receptors, Chimeric Antigen, T-Lymphocyte Subsets, Biological Products

Comments

This article has been corrected. See Nat Cancer. 2024 May 22.

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.